Skip to main content
Download PDF

Hypertension and urologic chronic pelvic pain syndrome: An analysis of MAPP-I data

BMC Urology volume 24, Article number: 21 (2024) Cite this article

Abstract

Background

Urologic chronic pelvic pain syndrome (UCPPS), which includes interstitial cystitis/bladder pain syndrome (IC/BPS) and chronic prostatitis (CP/CPPS), is associated with increased voiding frequency, nocturia, and chronic pelvic pain. The cause of these diseases is unknown and likely involves many different mechanisms. Dysregulated renin-angiotensin-aldosterone-system (RAAS) signaling is a potential pathologic mechanism for IC/BPS and CP/CPPS. Many angiotensin receptor downstream signaling factors, including oxidative stress, fibrosis, mast cell recruitment, and increased inflammatory mediators, are present in the bladders of IC/BPS patients and prostates of CP/CPPS patients. Therefore, we aimed to test the hypothesis that UCPPS patients have dysregulated angiotensin signaling, resulting in increased hypertension compared to controls. Secondly, we evaluated symptom severity in patients with and without hypertension and antihypertensive medication use.

Methods

Data from UCPPS patients (n = 424), fibromyalgia or irritable bowel syndrome (positive controls, n = 200), and healthy controls (n = 415) were obtained from the NIDDK Multidisciplinary Approach to the Study of Chronic Pelvic Pain I (MAPP-I). Diagnosis of hypertension, current antihypertensive medications, pain severity, and urinary symptom severity were analyzed using chi-square test and t-test.

Results

The combination of diagnosis and antihypertensive medications use was highest in the UCPPS group (n = 74, 18%), followed by positive (n = 34, 17%) and healthy controls (n = 48, 12%, p = 0.04). There were no differences in symptom severity based on hypertension in UCPPS and CP/CPPS; however, IC/BPS had worse ICSI (p = 0.031), AUA-SI (p = 0.04), and BPI pain severity (0.02). Patients (n = 7) with a hypertension diagnosis not on antihypertensive medications reported the greatest severity of pain and urinary symptoms.

Conclusion

This pattern of findings suggests that there may be a relationship between hypertension and UCPPS. Treating hypertension among these patients may result in reduced pain and symptom severity. Further investigation on the relationship between hypertension, antihypertensive medication use, and UCPPS and the role of angiotensin signaling in UCPPS conditions is needed.

Peer Review reports

Background

Urologic chronic pelvic pain syndrome (UCPPS) is characterized by persistent pelvic pain for at least three of the preceding six months, in the absence of other causes [1]. In addition to pelvic pain, patients may experience gastrointestinal and neuromuscular symptoms, impaired sexual and reproductive function, and hormonal derangements [2, 3]. Risk factors include a history of infection, chemical irritation, trauma or surgery, and pain may be exacerbated by anxiety, irritability, pain catastrophizing, and depression [4, 5]. While it is considered a common condition, symptomatology is similar to other painful conditions such as irritable bowel syndrome, fibromyalgia syndrome, and inflammatory bowel disease, which may also be comorbid [1]. Consequently, it is likely underdiagnosed, resulting in problems with bladder or urinary tract function, physical functioning, and reduced quality of life. UCPPS can be further subdivided into Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP/CPPS) and Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).

CP/CPPS has an estimated worldwide prevalence of 2–10% [6, 7]. It is characterized by prostate inflammation and/or infection, lower abdominal pain, pelvic pain, dysuria, urinary urgency, and frequency. IC/BPS has a higher prevalence among women than men, ranging from 0.045 to 6.5% in women and 0.008-4.2% in men [1, 8, 9]. It can present with severe pelvic pain, loss of bladder control, lower abdominal pain, lower back pain, and painful urination. Current treatment options for UCPPS have limited efficacy and are often associated with undesirable side effects.

Hypertension is often treated with medications that inhibit the renin-angiotensin signaling cascade, including angiotensin-converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARB). The renin-angiotensin-aldosterone system (RAAS) regulates blood pressure and volume. RAAS and activation of angiotensin type 1 receptor also contribute to the local generation of reactive oxidative stress, inflammation, and fibrosis in several organ systems, including the liver, lungs, and heart [10].

Little is known about the functional significance of local RAAS signaling in the bladder. Literature demonstrates that angiotensin II (Ang II), the signaling peptide in RAAS that activates angiotensin type 1 receptor, is produced locally in human and rat bladder tissue [11,12,13,14]. In pre-clinical models, angiotensin receptor type 1 and type 2 are expressed in the bladder, and activation of type 1, can induce detrusor contraction in pre-clinical models [15,16,17].

However, there are several intriguing links between IC/BPS pathology and RAAS, particularly Ang II signaling IC/BPS patients have increased mast cells in their bladder [18,19,20], representing a potential source of increased renin and Ang II [21, 22]. IC/BPS patients and animal disease models have increased oxidative stress in the bladder [23,24,25,26,27,28,29,30], and angiotensin signaling increases oxidative stress [31]. IC/BPS patients have increased expression of inflammatory mediators, which Ang II downstream signaling can release [1, 32,33,34,35,36].

Fibrosis is observed in patients with IC/BPS [18,19,20, 37,38,39,40,41], and Ang II signaling has been linked to fibrosis in heart [42], lungs [10], liver [43], and kidneys [44].

Therefore, we hypothesized that diseases with modified angiotensin signaling (hypertension) may have greater symptomology compared to normotensive patients and that patients treated with angiotensin modulators would have lower disease scores compared to those not on angiotensin modulators.

Herein we aim to understand the relationship between hypertension and UCPPS, and evaluate if there is an association between angiotensin signaling drugs and UCPPS symptom severity measures using cross-sectional data from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain I (MAPP- I) Research Network [45].

Methods

The Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network, which consists of multiple investigators across various fields, including urology, gynecology, rheumatology, gastroenterology, epidemiology, biology, and psychology was established by the National Institute of Health to evaluate the urological, non-urological, and psychosocial symptoms of patients suffering from UCPPS. This study uses data from the Epidemiology and Phenotyping (EP) study from the first phase of MAPP, also known as MAPP I [45]. Patients were enrolled from six sites in the United States over a three-year period (from December 14, 2009 through December 14, 2012, n = 1,039) [46]. Data were obtained from MAPP following approval by the University of Florida Institutional Review Board (IRB#202,200,510).

Participants

The study sample included healthy controls with no concomitant pain conditions (n = 415), positive controls with non-urologic (including fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome, n = 200), and patients with UCPPS (n = 424).

Measures

Demographics

During a baseline phenotyping visit, information including age, gender, ethnicity/race, educational level, current employment, and income was collected.

Health history and medications

Study participants’ health history, list of prescriptions and over-the-counter medications, and physical exam with vital signs, including blood pressure, were also collected during the baseline session.

Diagnosis of hypertension

Patients were identified as hypertensive based on self-reported diagnosis or a history of medications traditionally used to treat hypertension (ACE-i/ARB, beta-blockers) (Supplemental Table 1).

Symptom measures

Measures that indicate UCPPS symptom severity with consideration for variable reduction were selected.

Interstitial Cystitis Symptom Index (ICSI) and Interstitial Cystitis Problem Index (ICPI) [47]: The ICSI assesses the frequency of symptoms, and the ICPI assesses the impact of symptoms over the previous month, including bladder pain, urgency, frequency, and nocturia. ICSI scores range from 0 to 19 with higher scores indicating greater symptoms. ICPI scores range from 0 to 16 with higher scores indicating greater impact of symptoms. Measures in the analyses include the ICSI bladder pain symptom total (0–4 score) and the ICPI problem severity (0–4 score).

American Urological Association Symptom Index (AUA-SI) [48]: The AUA-SI consists of seven questions assessing urinary symptoms, including urgency, frequency, and voiding over the previous month on a 6-point Likert scale from 0 (“never”) to 5 (“almost always”). Total scores range from 0 to 35 with higher scores indicating more severe urinary symptomatology.

Genitourinary Pain Index (GUPI) [49]: The GUPI assesses genitourinary pain severity (PS), urinary symptoms (US), and quality of life (QOL) over the previous week. Scoring consists of three subscales, pain severity (0–23), urinary symptom severity (0–10), and quality of life impact (0–12) with total scores ranging from 0 to 45. Higher scores indicate greater pain, urologic symptoms, and worse quality of life. The three subscales and total score were included in the analyses.

Brief Pain Inventory (BPI) [50]: The BPI consists of a body map to indicate the areas of pain in the past 24 h. Measures of pain severity (average of worst, least, average, and right now) on a 0-no pain to a 10- pain as bad as you can imagine scale were collected. Pain interference is assessed specifically regarding general activity, mood, walking ability, normal work, relationships, sleep, and enjoyment of life from 0 – does not interfere to 10 – completely interferes. Pain medications and relief from pain medication in the past 24 h are also assessed. Pain severity and pain interference scores are included in the analyses.

Statistical analysis

Continuous measures were summarized as means and standard deviations and categorical measures were summarized as frequencies and percentages. Hypertension-related measures (hypertension diagnosis, anti-hypertension medication use) were compared across MAPP cohorts with chi-square tests. In the UCCPS cohort only, differences in pain related outcomes were compared between those with and without hypertension diagnosis [49], using t-tests. In the UCCPS cohort, participants with diagnosed hypertension, pain-related outcomes were compared between those who reported taking antihypertensive medication and those that did not, using Mann-Whitney tests. Subgroup analysis of CP/CPPS and IC/BPS was performed. Hypertensive patients who were not on medication were age-matched to patients using antihypertensives. P < 0.05 was considered statistically significant. Analyses were conducted in JMP Pro 16 (SAS Institute Inc, Cary NC) and R statistical software (4.2.3).

Results

There were 415 healthy controls, 200 positive controls, and 424 UCPPS patients (Table 1). The average age was 40.5 ± 14.1 for healthy controls, 41.7 ± 13.7 years for positive controls, and 43.4 ± 15.1 for UCPPS. Positive controls were mostly female (78% vs. 56.1% for healthy controls and 55% for UCPPS). All three cohorts were predominantly white (healthy controls 76.1%, positive controls 75%, and UCPPS 88.2%) of non-Hispanic ethnicity (91.6%, 93%, and 93%, respectively). Educational levels were similar across the three groups; however, unemployment rates were lowest in the UCPPS group (14% vs. 21% for controls). UCPPS patients were further subdivided into CP/CPPS (11.3%, n = 48), IC/BPS (55.2%, n = 234), and both (33.5%, n = 142) (Table 2).

Table 1 Demographic characteristics of healthy controls, positive controls and urologic chronic pelvic pain syndrome patients
Full size table
Table 2 Demographic characteristics of Chronic Prostatitis-Chronic Pelvic Pain Syndrome and Interstitial Cystitis-Bladder Pain Syndrome patients
Full size table

Incidence of hypertension

Positive controls had the highest incidence of hypertension (n = 29, 15%), followed by UCPPS (n = 50, 12%) and healthy controls (n = 40, 10%); however, this was not statistically significant (X2(2, n = 1,035) = 3.16, p = 0.21). Within UCPPS, 8.3% (n = 4) with CP/CPPS and 8.6% (n = 20) with IC/BPS had a diagnosis of hypertension (X2(1, n = 282) = 0.002, p = 0.96)

Use of antihypertensive medications was similar across the three groups (n = 40, 16% healthy controls vs. 17% in positive controls (n = 29) and UCPPS (n = 66) (X2(2, n = 821) = 0.26, p = 0.87). Among UCPPS patients, 19% (n = 6) of CP/CPPS and 14% (n = 27) of IC/BPS patients used antihypertensive medication (X2(1, n = 253) = 0.73, p = 0.39)

The combination of diagnosis and use of antihypertensive medications was highest in the UCPPS group (n = 74, 18%), followed by positive controls (n = 34, 17%) and healthy controls (n = 48, 12%), (X2(2, n = 1,039) = 6.46, p = 0.04). Of CP/CPPS patients, 12.5% (n = 6) had a diagnosis or were on antihypertensives, and 13.2% (n = 31) of IC/BPS (X2(1, n = 282) = 0.02, p = 0.89)

The incidence of angiotensin receptor blockers (ARB) use was greatest among UCPPS group (4%, n = 15) vs. 1% (n = 2) for healthy controls, 0% for positive controls, p = 0.002); while the rates of ACE inhibitor (ACE-i) use was similar (8% for each control group, 5% UCPPS) (X2(2, n = 821) = 2.81, p = 0.25)

When comparing healthy controls to UCPPS patients, ARB use (p = 0.02), along with combined self-reported hypertension/antihypertensive use (p = 0.02) were significantly higher in the UCPPS group, while ACE-I use was higher among healthy controls (p = 0.02)

Hypertension and UCPPS symptom severity

Diagnosis of hypertension was not significantly associated with symptom severity in UCPPS with consideration of the following measures: ICSI, ICPI, AUA-SI, GUPI (QOL, pain severity, urinary severity, and total score), or BPI (pain severity and interference, Fig. 1A-C). Similarly, there were no differences in pain-related outcomes based on hypertension among CP/CPPS.

Fig. 1
figure 1

ICSI, AUA-SI, and BPI pain severity were significantly higher in IC/BPS patients with hypertension. Differences in (A) ICSI, AUA-SI, and (C) BPI based on hypertension. The circle represents the mean and the error bars represent 95% confidence intervals. Black stars denote significant differences between hypertensive and normotensive patients. Confidence intervals that cross the dotted red line are considered non-significant

Full size image

However, patients diagnosed with hypertension and IC/BPS had significantly worse symptom severity based on the ICSI (difference 1.87, 95% CI 0.17–3.57, p = 0.031), AUA-SI (1.65, 95% CI 0.16–6.64, p = 0.04), and BPI Pain severity score (0.85, 95% CI 0.12–1.58, p = 0.022), but not ICPI, BPI Pain interference or GUPI (QOL, pain severity, urinary severity, and total score).

Use of antihypertensive medications and symptom severity

Age-matched patients who were diagnosed with hypertension, but were not using antihypertensives (n = 7) had higher symptom severity specific to ICSI (p = 0.04), ICPI (p = 0.02), AUA-SI (p = 0.03), GUPI urinary severity (p = 0.035), total GUPI (p = 0.037), while GUPI QOL impact (p = 0.08) trended toward significance (Fig. 2). There were no significant differences in GUPI pain severity (p = 0.12), BPI pain severity (p = 0.22), or pain interference (p = 0.35). There were also no differences in symptom severity based on the use of ACE-i/ARB compared to other antihypertensive medications. Of age matched patients with hypertension who were not using antihypertensives, 4 had IC/BPS, and 3 had CP/CPPS. In addition, of these patients, 5 of 7 had elevated blood pressures (> 130/80) at the time of initial evaluation.

Fig. 2
figure 2

ICSI, ICPI, AUA-SI, GUPI urinary severity, and total score were significantly higher for hypertensive UCPPS patients not on antihypertensives compared to those who were. Differences in ICSI, ICPI, AUA-SI, GUPI, and BPI outcomes among hypertensive UCPPS patients based on antihypertensive medication use. The circle represents the mean, and the error bars represent 95% confidence intervals. Black stars denote significant differences between hypertensive and normotensive patients. Confidence intervals that cross the dotted red line are considered non-significant

Full size image

Discussion

In this study, we evaluated the relationship between hypertension and UCPPS, and whether a diagnosis of hypertension and/or use of antihypertensive medications is related to symptom severity. As the sample sizes were small, findings warrant interpretation as preliminary and do not demonstrate a cause and effect relationship. We observed a non-significant trend suggesting the incidence of hypertension was higher among positive controls and UCPPS patients compared to healthy controls. Additionally, ARB use was greater among the UCPPS group compared to positive and healthy controls. Hypertension was associated with higher symptom severity among patients with IC/BPS, but not UCPPS in general or CP/CPPS alone. Furthermore, the seven UCPPS individuals with hypertension who were not on antihypertensives reported significantly worse symptom severity compared to those receiving treatment. Finally, we did not detect a difference in symptom severity based on the use of ACE-i/ARB.

Hypertension as a comorbidity of UCPPS

Among the MAPP-I cohort, 18% of UCPPS patients (12.5% CP/CPPS and 13.2% IC/BPS), 17% of positive controls, and 12% of healthy controls were diagnosed with hypertension or used antihypertensive medication; however, there were no significant differences between these groups. While studies evaluating hypertension in UCPPS are minimal, our findings regarding CP/CPPS are similar to those reported in the Health Professionals Follow Up study, where no differences in hypertension were noted after adjustment for smoking and BMI [51]. Similarly, a study of male participants in China found no difference in the prevalence of hypertension in those diagnosed with CP/CPPS compared to controls [52]. In contrast, Pontari et al. demonstrated an 11% lifetime prevalence of cardiovascular diseases among CP/CPPS patients compared to 2% in age-matched controls; however, while they note hypertension was the most common condition, they do not distinguish further [4]. Similarly, a study from Taiwan found that CP/CPPS patients had a higher prevalence of hypertension compared to controls [53].

Also completed in Taiwan, a study of patients with IC/BPS found no difference in rates of hypertension between patients with IC/BPS and controls [54]. Similarly, in a study of Brazilian individuals, there were no differences in self-reported hypertension [55]. In contrast, a recent study from China found that the prevalence of hypertension in IC/BPS was 30.8% compared to 13.2% among age and parity-matched controls [56]. Another study similarly found a greater prevalence of hypertension among subjects with IC/BPS compared to controls [57]. The greater prevalence of hypertension in UCPPS patients compared to controls without a significant difference could be due to the smaller sample size represented in this cohort. Furthermore, hypertension prevalence in the US is estimated to be 45.4%, which is significantly higher compared to the controls in our study, potentially due in part to the age representation, female predominance, and greater educational level, all of which are associated with lower rates of hypertension [58].

Use of antihypertensives in UCPPS patients and controls

Next, among the MAPP-I cohort, 4% of UCPPS patients used ARBs, and 5% used ACE-i, which is in contrast to the healthy controls where 1% used ARBs and 8% used ACE-i. This finding among UCPPS patients also differs from the literature where ACE-i are more commonly prescribed [59].

Hypertension and UCPPS symptom severity

Hypertension was associated with worse symptom severity in IC/BPS patients but not CP/CPPS or overall UCPPS patients. No differences were noted in symptom severity based on the medication used (Fig. 1). Similarly, a study stratifying CP/CPPS by intensity of pain did not find hypertension to be a significant risk factor [60]. It is important to note that in the general public, only 40% of patients on antihypertensives have well-controlled blood pressure. It is also possible that despite taking an antihypertensive, the medication is insufficient to control deregulated hormones and does not contribute to symptom severity outcomes [61].

Antihypertensives and UCPPS symptom severity

Finally, although interpretation is limited by the sample size, age-matched UCPPS hypertensive patients not on anti-hypertensives had worse symptom severity compared to those who were treated with antihypertensives, which has not been reported previously. Prior studies evaluating the relationship between pain, which is the most common domain within the symptom severity outcomes, and hypertension had mixed results. Some studies demonstrate a positive relationship between pain and hypertension, some demonstrate decreased pain perception, while others demonstrate no association [62]. It is possible that untreated, hypertensive patients have greater levels of angiotensin II and aldosterone which can further potentiate inflammation, dysregulate the hypothalamic-pituitary-adrenal axis, and contribute toward worse symptom severity [63].

For example, Dimitrakov et al. evaluated 27 CP/CPPS patients and 20 age matched asymptomatic controls and found that CP/CPPS patients, in general had lower corticosterone and aldosterone levels, and higher progesterone levels compared to controls [64]. However, in CP/CPPS patients, higher NIH-CPSI total and pain domain scores (indicating worse symptom severity) were associated with greater aldosterone levels [64]. Prior mouse studies demonstrated that aldosterone production leads to hypersensitivity and likely contributes to pain signaling [65].

In regards to ACE-i compared to ARBs, our UCPPS cohort tended to use ACE-i more than healthy controls. While this could be a coincidence, ACE-i may be implicated in decreased breakdown of bradykinin and it is possible that these patients exhibited more side-effects from ACE-i use [66]. However, the sample size was not large enough to further differentiate the effects between ACE-i, ARB, and other antihypertensives.

Limitations and future directions

There are several limitations to acknowledge. First, this study is limited by a small sample size and can only be considered a preliminary investigation. By definition of a retrospective cohort, the study design is unable to demonstrate a cause and effect relationship, only associations. There is also limited minority ethnic and race group representation in this sample, further limiting generalizability to the diverse U.S. population.

Next, self-reported diagnosis of hypertension is subject to recall bias, and these patients could be misclassified. In addition, while we eliminated medications not traditionally used as antihypertensives, it is possible that individuals are misclassified as having hypertension based on their medication use. Conversely, it is also possible that some patients are using non-traditional medications for their hypertension and are misclassified as normotensive. Furthermore, it is possible patients developed hypertension at a later time period from when the initial evaluation was completed. In addition, we do not have longitudinal medication data to determine whether individuals were started on additional pain medications, on another antihypertensive medication, and/or if medications were stopped or switched.

Third, the reported rates of hypertension are significantly lower compared to the general population across all three cohorts, possibly indicating a lack of external generalizability. It is also unknown why the prevalence of ARB use was significantly higher in the UCPPS group compared to the other two groups, although it may be related to hypertension control. Fourth, of the patients who are considered hypertensive, who were not on medication, two of seven did not have elevated blood pressure (systolic ≥ 130mmHg and/or diastolic ≥ 80mmHg) at the baseline visit, meaning that their hypertension may be controlled by lifestyle modifications. Finally, hypertension is only one factor which may contribute to the patient’s experience of pain- elevated blood glucose, presence of inflammation, obesity and many others were not included and should be evaluated in future studies.

While this study is among the largest evaluating the incidence of hypertension in UCPPS, and evaluating the impact of hypertension on symptom severity, sample sizes to address the questions of interest were small. We were limited in identifying the relationship between symptom severity and specific medications, and whether hypertension control helps regulate pain severity. Furthermore, prospectively evaluating whether there is improvement in pelvic pain symptoms for hypertensive UCPPS patients when they are placed on ACE-i or ARB compared to other pain management strategies would be an important next step. Further investigation in these areas is needed. If these relationships prove true, treating UCPPS patients with antihypertensive medications as part of the treatment regimen might help reduce pain and improve symptom management.

Conclusion

UCCPS may be co-morbid to hypertension or the use of antihypertensive drugs. The use of antihypertensive medications was associated with a reduction in symptoms and pain severity in a small sample. Based on pre-clinical data and our preliminary findings, further investigations with larger sample sizes on the relationship between hypertension and UCPPS and the effects of different medications on symptom severity are needed.

Data availability

Data from the Multidisciplinary Approach to the Study of Pelvic Pain [(V4)/https://doi.org/10.58020/emxg-8065] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.

Abbreviations

UCPPS:

Urologic chronic pelvic pain syndrome

IC/BPS:

Interstitial cystitis/bladder pain syndrome

CP/CPPS:

Chronic prostatitis

ACE-i:

Angiotensin-converting enzyme inhibitors

ARB:

Angiotensin receptor blockers

ICSI:

Interstitial Cystitis Symptom Index

ICPI:

Interstitial Cystitis Problem Index

AUA-SI:

American Urological Association Symptom Index

GUPI:

Genitourinary Pain Index

QOL:

Quality of life

BPI:

Brief Pain Inventory

MAPP:

Multidisciplinary Approach to the Study of Chronic Pelvic Pain I

RAAS:

Renin-Angiotensin-Aldosterone-System

Ang II:

Angiotensin II

References

  1. Clemens JQ, Mullins C, Ackerman AL, Bavendam T, van Bokhoven A, Ellingson BM, Harte SE, Kutch JJ, Lai HH, Martucci KT, et al. Urologic chronic pelvic pain syndrome: insights from the MAPP Research Network. Nat Rev Urol. 2019;16(3):187–200.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Condorelli RA, Russo GI, Calogero AE, Morgia G, La Vignera S. Chronic prostatitis and its detrimental impact on sperm parameters: a systematic review and meta-analysis. J Endocrinol Invest. 2017;40(11):1209–18.

    Article  CAS  PubMed  Google Scholar 

  3. Bartoletti R, Cai T, Mondaini N, Dinelli N, Pinzi N, Pavone C, Gontero P, Gavazzi A, Giubilei G, Prezioso D, et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. J Urol. 2007;178(6):2411–5. discussion 2415.

    Article  PubMed  Google Scholar 

  4. Pontari MA, McNaughton-Collins M, O’Leary MP, Calhoun EA, Jang T, Kusek JW, Landis JR, Knauss J, Litwin MS. A case-control study of risk factors in men with chronic pelvic pain syndrome. BJU Int. 2005;96(4):559–65.

    Article  PubMed  Google Scholar 

  5. Huang X, Qin Z, Cui H, Chen J, Liu T, Zhu Y, Yuan S. Psychological factors and pain catastrophizing in men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a meta-analysis. Transl Androl Urol. 2020;9(2):485–93.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Krieger JN, Riley DE, Cheah PY, Liong ML, Yuen KH. Epidemiology of prostatitis: new evidence for a world-wide problem. World J Urol. 2003;21(2):70–4.

    Article  PubMed  Google Scholar 

  7. Smith CP. Male chronic pelvic pain: an update. Indian J Urol. 2016;32(1):34–9.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, Nyberg L, Clemens JQ. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186(2):540–4.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Anger JT, Dallas KB, Bresee C, De Hoedt AM, Barbour KE, Hoggatt KJ, Goodman MT, Kim J, Freedland SJ. National prevalence of IC/BPS in women and men utilizing veterans health administration data. Front Pain Res (Lausanne). 2022;3:925834.

    Article  PubMed  Google Scholar 

  10. Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respir Crit Care Med. 2000;161(6):1999–2004.

    Article  CAS  PubMed  Google Scholar 

  11. Weaver-Osterholtz D, Reams G, Wu Z, Knaus J, Campbell F, Bauer JH. The urinary bladder angiotensin system: response to infusions of angiotensin I and angiotensin-converting enzyme inhibitors. Am J Kidney Dis. 1996;28(4):603–9.

    Article  CAS  PubMed  Google Scholar 

  12. Lindberg BF, Nilsson LG, Hedlund H, Stahl M, Andersson KE. Angiotensin-I is converted to Angiotensin-Ii by a serine-protease in human detrusor smooth-muscle. Am J Physiol. 1994;266(6):R1861–7.

    CAS  PubMed  Google Scholar 

  13. Cheng EY, Decker RS, Lee C. Role of angiotensin II in bladder smooth muscle growth and function. Adv Exp Med Biol. 1999;462:183–91.

    Article  CAS  PubMed  Google Scholar 

  14. Comiter CV, Sullivan MP, Yalla SV, Kifor I. Effect of angiotensin II on corpus cavernosum smooth muscle in relation to nitric oxide environment: in vitro studies in canines. Int J Impot Res. 1997;9(3):135–40.

    Article  CAS  PubMed  Google Scholar 

  15. Aikawa K, Sakai T, Ishibashi K, Shiomi H, Sagawa K, Kumagai S, Kataoka M, Akaihata H, Yamaguchi O. Involvement of angiotensin II type 1 receptor on pathological remodeling and dysfunction in obstructed bladder. Int J Urol. 2012;19(5):457–64.

    Article  CAS  PubMed  Google Scholar 

  16. Hadzhibozheva P, Tolekova A, Kalfin R, Georgiev T. Analysis of angiotensin II-Induced rat urinary bladder contractions in the presence of angiotensin II receptors blockers. Arch Physiol Biochem. 2021;127(1):1–5.

    Article  CAS  PubMed  Google Scholar 

  17. Lim I, Mitsui R, Kameda M, Sellers DJ, Chess-Williams R, Hashitani H. Comparative effects of angiotensin II on the contractility of muscularis mucosae and detrusor in the pig urinary bladder. Neurourol Urodyn. 2021;40(1):102–11.

    Article  CAS  PubMed  Google Scholar 

  18. Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology. 2001;57(6 Suppl 1):47–55.

    Article  CAS  PubMed  Google Scholar 

  19. Richter B, Roslind A, Hesse U, Nordling J, Johansen JS, Horn T, Hansen AB. YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. Histopathology. 2010;57(3):371–83.

    Article  PubMed  Google Scholar 

  20. Kim A, Han JY, Ryu CM, Yu HY, Lee S, Kim Y, Jeong SU, Cho YM, Shin DM, Choo MS. Histopathological characteristics of interstitial cystitis/bladder pain syndrome without Hunner lesion. Histopathology. 2017;71(3):415–24.

    Article  PubMed  Google Scholar 

  21. Miyazaki M, Takai S, Jin D, Muramatsu M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther. 2006;112(3):668–76.

    Article  CAS  PubMed  Google Scholar 

  22. Silver RB, Reid AC, Mackins CJ, Askwith T, Schaefer U, Herzlinger D, Levi R. Mast cells: a unique source of renin. Proc Natl Acad Sci U S A. 2004;101(37):13607–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ener K, Keske M, Aldemir M, Ozcan MF, Okulu E, Ozayar A, Ergin M, Doluoglu OG, Cakmak S, Erel O. Evaluation of oxidative stress status and antioxidant capacity in patients with painful bladder syndrome/interstitial cystitis: preliminary results of a randomised study. Int Urol Nephrol. 2015;47(8):1297–302.

    Article  CAS  PubMed  Google Scholar 

  24. Ehren I, Hosseini A, Lundberg JO, Wiklund NP. Nitric oxide: a useful gas in the detection of lower urinary tract inflammation. J Urol. 1999;162(2):327–9.

    Article  CAS  PubMed  Google Scholar 

  25. Bae WJ, Ha US, Kim S, Kim SJ, Hong SH, Lee JY, Hwang TK, Hwang SY, Kim HJ, Kim SW. Reduction of oxidative stress may play a role in the anti-inflammatory effect of the novel herbal formulation in a rat model of hydrochloric acid-induced cystitis. Neurourol Urodyn. 2015;34(1):86–91.

    Article  PubMed  Google Scholar 

  26. Zeybek A, Saglam B, Cikler E, Cetinel S, Ercan F, Sener G. Taurine ameliorates stress-induced degeneration of the urinary bladder. Acta Histochem. 2007;109(3):208–14.

    Article  CAS  PubMed  Google Scholar 

  27. Zhang QH, Zhou ZS, Lu GS, Song B, Guo JX. Melatonin improves bladder symptoms and may ameliorate bladder damage via increasing HO-1 in rats. Inflammation. 2013;36(3):651–7.

    Article  CAS  PubMed  Google Scholar 

  28. Bazi T, Hajj-Hussein IA, Awwad J, Shams A, Hijaz M, Jurjus A. A modulating effect of epigallocatechin gallate (EGCG), a tea catechin, on the bladder of rats exposed to water avoidance stress. Neurourol Urodyn. 2013;32(3):287–92.

    Article  CAS  PubMed  Google Scholar 

  29. de Oliveira MG, Calmasini FB, Alexandre EC, De Nucci G, Monica FZ, Antunes E. Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice. Am J Physiol Renal Physiol. 2016;311(1):F85–93.

    Article  PubMed  Google Scholar 

  30. Birder LA, Wolf-Johnston A, Buffington CA, Roppolo JR, de Groat WC, Kanai AJ. Altered inducible nitric oxide synthase expression and nitric oxide production in the bladder of cats with feline interstitial cystitis. J Urol. 2005;173(2):625–9.

    Article  CAS  PubMed  Google Scholar 

  31. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2(7):247–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Dagher A, Curatolo A, Sachdev M, Stephens AJ, Mullins C, Landis JR, van Bokhoven A, El-Hayek A, Froehlich JW, Briscoe AC, et al. Identification of novel non-invasive biomarkers of urinary chronic pelvic pain syndrome: findings from the Multidisciplinary Approach to the study of Chronic Pelvic Pain (MAPP) Research Network. BJU Int. 2017;120(1):130–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Xu S, Wang X, Wang Y, Lutgendorf S, Bradley C, Schrepf A, Kreder K, O’Donnell M, Luo Y. Transgenic mice expressing MCP-1 by the Urothelium demonstrate bladder hypersensitivity, Pelvic Pain and Voiding Dysfunction: a Multidisciplinary Approach to the study of Chronic Pelvic Pain Research Network Animal Model Study. PLoS ONE. 2016;11(9):e0163829.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Ogawa T, Homma T, Igawa Y, Seki S, Ishizuka O, Imamura T, Akahane S, Homma Y, Nishizawa O. CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. J Urol. 2010;183(3):1206–12.

    Article  CAS  PubMed  Google Scholar 

  35. Bosch PC. Examination of the significant placebo effect in the treatment of interstitial cystitis/bladder pain syndrome. Urology. 2014;84(2):321–6.

    Article  PubMed  Google Scholar 

  36. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens. 2007;21(1):20–7.

    Article  CAS  PubMed  Google Scholar 

  37. Kim A, Yu HY, Lim J, Ryu CM, Kim YH, Heo J, Han JY, Lee S, Bae YS, Kim JY, et al. Improved efficacy and in vivo cellular properties of human embryonic stem cell derivative in a preclinical model of bladder pain syndrome. Sci Rep. 2017;7(1):8872.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Song M, Lim J, Yu HY, Park J, Chun JY, Jeong J, Heo J, Kang H, Kim Y, Cho YM, et al. Mesenchymal stem cell therapy alleviates interstitial cystitis by activating wnt signaling pathway. Stem Cells Dev. 2015;24(14):1648–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Choi D, Han JY, Shin JH, Ryu CM, Yu HY, Kim A, Lee S, Lim J, Shin DM, Choo MS. Downregulation of WNT11 is associated with bladder tissue fibrosis in patients with interstitial cystitis/bladder pain syndrome without Hunner lesion. Sci Rep. 2018;8(1):9782.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Ryu CM, Shin JH, Yu HY, Ju H, Kim S, Lim J, Heo J, Lee S, Shin DM, Choo MS. N-acetylcysteine prevents bladder tissue fibrosis in a lipopolysaccharide-induced cystitis rat model. Sci Rep. 2019;9(1):8134.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Bullock AD, Becich MJ, Klutke CG, Ratliff TL. Experimental autoimmune cystitis: a potential murine model for ulcerative interstitial cystitis. J Urol. 1992;148(6):1951–6.

    Article  CAS  PubMed  Google Scholar 

  42. Jiang HM, Wang HX, Yang H, Zeng XJ, Tang CS, Du J, Li HH. Role for granulocyte colony stimulating factor in angiotensin II-induced neutrophil recruitment and cardiac fibrosis in mice. Am J Hypertens. 2013;26(10):1224–33.

    Article  CAS  PubMed  Google Scholar 

  43. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34(4 Pt 1):745–50.

    Article  CAS  PubMed  Google Scholar 

  44. Macconi D, Remuzzi G, Benigni A. Key fibrogenic mediators: old players. Renin-angiotensin system. Kidney Int Suppl (2011) 2014, 4(1):58–64.

  45. Landis R. Multidisciplinary Approach to the study of Pelvic Pain (V4) [Dataset]. In.: NIDDK Central Repository; 2023.

  46. Multi-Disciplinary Approach to the Study of. Chronic Pelvic Pain [https://www.mappnetwork.org/].

  47. O’Leary MP, Sant GR, Fowler FJ Jr., Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997;49(5A Suppl):58–63.

    Article  PubMed  Google Scholar 

  48. Madsen FA, Bruskewitz RC. Clinical manifestations of benign prostatic hyperplasia. Urol Clin North Am. 1995;22(2):291–8.

    Article  CAS  PubMed  Google Scholar 

  49. Clemens JQ, Calhoun EA, Litwin MS, McNaughton-Collins M, Kusek JW, Crowley EM, Landis JR. Validation of a modified National Institutes of Health chronic prostatitis symptom index to assess genitourinary pain in both men and women. Urology. 2009;74(5):983–7. quiz 987 e981-983.

    Article  PubMed  Google Scholar 

  50. Cleeland CS, Ryan KM. Pain assessment: global use of the brief Pain Inventory. Ann Acad Med Singap. 1994;23(2):129–38.

    CAS  PubMed  Google Scholar 

  51. Zhang R, Sutcliffe S, Giovannucci E, Willett WC, Platz EA, Rosner BA, Dimitrakoff JD, Wu K. Lifestyle and risk of Chronic Prostatitis/Chronic Pelvic Pain Syndrome in a cohort of United States Male Health professionals. J Urol. 2015;194(5):1295–300.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Wang Y, He L, Zhou Z, Jin L, Meng J, Sun G, Na Y. The association between metabolic syndrome and the National institutes of Health Chronic Prostatitis Symptom Index: results from 1673 men in China. Urology. 2013;82(5):1103–7.

    Article  PubMed  Google Scholar 

  53. Chung SD, Lin HC. Association between chronic prostatitis/chronic pelvic pain syndrome and anxiety disorder: a population-based study. PLoS ONE. 2013;8(5):e64630.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Huang CY, Chung SD, Kao LT, Lin HC, Wang LH. Statin use is Associated with bladder Pain Syndrome/Interstitial cystitis: a Population-based case-control study. Urol Int. 2015;95(2):227–32.

    Article  CAS  PubMed  Google Scholar 

  55. Da Luz RA, de Deus JM, Conde DM. Quality of life and associated factors in Brazilian women with chronic pelvic pain. J Pain Res. 2018;11:1367–74.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Peng L, Di XP, He SX, Zeng X, Shen H, Zhu HL, Luo DY. Metabolic syndrome in women with and without interstitial cystitis/bladder pain syndrome. Int Urogynecol J. 2020;32(5):1299–306.

    Article  PubMed  Google Scholar 

  57. Chen HM, Lin CC, Kang CS, Lee CT, Lin HC, Chung SD. Bladder pain syndrome/interstitial cystitis increase the risk of coronary heart disease. Neurourol Urodyn. 2013;33(5):511–5.

    Article  CAS  PubMed  Google Scholar 

  58. Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among adults aged 18 and over: United States, 2017–2018. NCHS Data Brief 2020(364):1–8.

  59. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126(17):2105–14.

    Article  CAS  PubMed  Google Scholar 

  60. Chen J, Zhang H, Niu D, Li H, Wei K, Zhang L, Yin S, Liu L, Zhang X, Zhang M, et al. The risk factors related to the severity of pain in patients with chronic Prostatitis/Chronic Pelvic Pain Syndrome. BMC Urol. 2020;20(1):154.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Chobufo MD, Gayam V, Soluny J, Rahman EU, Enoru S, Foryoung JB, Agbor VN, Dufresne A, Nfor T. Prevalence and control rates of hypertension in the USA: 2017–2018. Int J Cardiol Hypertens. 2021;6:100044.

    Article  Google Scholar 

  62. Navarro-Ledesma S, Gonzalez-Munoz A, Garcia Rios MC, de la Serna D, Pruimboom L. Circadian variation of blood pressure in patients with Chronic Musculoskeletal Pain: a cross-sectional study. Int J Environ Res Public Health 2022, 19(11).

  63. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol. 2009;5(7):374–81.

    Article  CAS  PubMed  Google Scholar 

  64. Dimitrakov J, Joffe HV, Soldin SJ, Bolus R, Buffington CA, Nickel JC. Adrenocortical hormone abnormalities in men with chronic prostatitis/chronic pelvic pain syndrome. Urology. 2008;71(2):261–6.

    Article  PubMed  Google Scholar 

  65. Shaqura M, Li L, Mohamed DM, Li X, Treskatsch S, Buhrmann C, Shakibaei M, Beyer A, Mousa SA, Schafer M. Neuronal aldosterone elicits a distinct genomic response in pain signaling molecules contributing to inflammatory pain. J Neuroinflammation. 2020;17(1):183.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Bali A, Singh N, Jaggi AS. Renin-angiotensin system in pain: existing in a double life? J Renin Angiotensin Aldosterone Syst. 2014;15(4):329–40.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Henry Lai for reviewing our manuscript and providing helpful feedback.

Funding

This work was supported by DK132003 and grant from the Rita Allen Foundation Scholars Program Fund, a component fund of the Community Foundation of New Jersey (AM). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author information

Authors and Affiliations

  1. Department of Physical Medicine and Rehabilitation, College of Medicine, University of Florida, Gainesville, FL, USA

    Rosalynn R.Z. Conic, Andrew Dubin & Kimberly T. Sibille

  2. Department of Orthopaedic Surgery and Sports Medicine, University of Florida, Gainesville, FL, USA

    Terrie Vasilopoulos

  3. Department of Anesthesiology, Division of Pain Medicine, University of Florida, Gainesville, FL, USA

    Terrie Vasilopoulos, Rene Przkora & Kimberly T. Sibille

  4. Department of Physiological Sciences, College of Veterinary Medicine, University of Florida, PO Box 100144, Gainesville, FL, 32610, USA

    Karthik Devulapally & Aaron D. Mickle

  5. Department of Biomedical Engineering, College of Engineering, University of Florida, Gainesville, FL, USA

    Aaron D. Mickle

  6. Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, USA

    Aaron D. Mickle

Authors
  1. Rosalynn R.Z. Conic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Terrie Vasilopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karthik Devulapally
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rene Przkora
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrew Dubin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kimberly T. Sibille
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Aaron D. Mickle
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The authors confirm contribution to the paper as follows: study conception and design: AM, KS, AD, RP, TV, RC, KD; obtained data: AM; data analysis: RC, TV, KD; interpretation of results: RC, TV, AM, KS, KD, AD, RP; draft manuscript preparation: RC, AM. All authors reviewed the results and approved the final version of the manuscript.

Corresponding author

Correspondence to Aaron D. Mickle.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the University of Florida Institutional Review Board (IRB#202200510).

Consent for publication

Not Applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Conic, R.R., Vasilopoulos, T., Devulapally, K. et al. Hypertension and urologic chronic pelvic pain syndrome: An analysis of MAPP-I data. BMC Urol 24, 21 (2024). https://doi.org/10.1186/s12894-024-01407-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12894-024-01407-w

Keywords

BMC Urology

ISSN: 1471-2490

Contact us